Axatilimab  (Synonyms: SNDX-6352)

Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

Axatilimab (SNDX-6352) affects the migration, proliferation, differentiation, and survival of monocytes and macrophages by binding to CSF-1R and blocking its activation by its two known ligands, CSF-1 and IL-34^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2155851-88-8

Liquid

Colorless to light yellow

[Axatilimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Loaded CSF1R Protein, Human (HEK293, His-Fc, HY-P75323) on HIS1K biosensor, can bind Axatilimab with an affinity constant of 1.467E-11 M as determined in BLI assay.

• [1]. Arora M, et al. Phase 1 study of axatilimab (SNDX-6352), a CSF-1R humanized antibody, for chronic graft-versus-host disease after 2 or more lines of systemic treatment. Blood, 2020, 136: 1-2.

  [2]. Tiessen R, et al. First in human, single ascending dose study in healthy volunteers of SNDX-6352, a humanized IgG4 monoclonal antibody targeting colony stimulating factor-1 receptor (CSF-1R). J Immunother Cancer, 2016, 5: P505.